Home > Drugs A – Z > Atomoxetine (By mouth)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD) in children, teenagers, and adults. It belongs to the group of medicines called selective norepinephrine reuptake inhibitors. Atomoxetine works in the brain to increase attention and decrease restlessness in people who are hyperactive, have problems with concentration, or are easily distracted. This medicine may be used… Read more
Brand names include
Strattera, atomoxetine hydrochloride
Drug classes About this
Central Nervous System Agent

What works? Research summarized

Evidence reviews

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

Attention deficit hyperactivity disorder (ADHD) (including hyperkinetic disorder) is defined by the 'core' signs of inattention, hyperactivity and impulsivity, and is characterised by an early onset. The estimated prevalence for ADHD in school-aged children varies widely (e.g. 3-7%), being dependent on a number of variables, including the methods of ascertainment, the informants, the population sampled, the diagnostic criteria applied and the sex of the affected individual. Data on prevalence in adolescence and adulthood are limited. The disorder is frequently observed in greater numbers of males than females, with ratios ranging from 2:1 to 9:1 depending on subtype and setting.

Drug treatments for chronic cognitive impairment in traumatic brain injury

Background: Traumatic brain injury (TBI) is a major cause of long‐term disability across the world. The disability is often related to chronic cognitive impairment, such as changes to memory, attention and problem solving.

Guanfacine Hydrochloride Extended Release (Intuniv XR) Tablets: For the Treatment of Attention-Deficit/Hyperactivity Disorder [Internet]

The objective of this review was to compare the clinical benefits and harms of guanfacine extended release (GXR; brand name: Intuniv XR) with those of other active treatments and placebo in children aged six to 12 years with attention-deficit/hyperactivity disorder (ADHD).

See all (65)

Summaries for consumers

Drug treatments for chronic cognitive impairment in traumatic brain injury

Background: Traumatic brain injury (TBI) is a major cause of long‐term disability across the world. The disability is often related to chronic cognitive impairment, such as changes to memory, attention and problem solving.

Treatment Options for ADHD in Children and Teens: A Review of Research for Parents and Caregivers

This summary discusses the different types of treatment for ADHD. It explains what research says about how each treatment improves symptoms and the risks involved with each treatment. It can help you talk with the doctor about ADHD and your child.

Medications for attention deficit hyperactivity disorder (ADHD) in children with tics

As many as half of all children with tic disorders (a combination of repetitive motions vocalizations), also have ADHD (issues with hyperactivity, impulsivity and maintaining attention). Symptoms of ADHD are often more disabling for children than their tics. Historically, the reported ability of stimulant medications to worsen tics has limited their use in children who have both a chronic tic disorder (lasting over a year since the first tic onset) and ADHD. To evaluate evidence for this reported phenomenon, we searched for clinical trials of medications for ADHD used specifically in children with tic disorders.

See all (12)

PubMed Health Blog...

read all...